The various subtypes of receptors for catecholamines, termed adrenergic receptors, represent excellent models for the study of receptor-mediated transmembrane signalling because of their ubiquity, their coupling to well-defined effector mechanisms, and the clinical importance of drugs which interact with them. In general, the adrenergic receptor systems consist of three components which are coupled to each other: (i) the receptor, to which the hormone binds; (ii) a guanine nucleotide regulatory protein (or G-protein) and (iii) an effector enzyme.
[ 1-51, as well as other related receptors of this family 16-81. From these efforts it became apparent that these receptors are part of a large gene family, including the muscarinic acetylcholine, angiotensin and lutropin receptors. The proteins encoded by these genes possess a distinctive structure with seven putative transmembrane domains connected by Abbreviations used: PKA, protein kinase; PIP2, phosphoinositol bisphosphate; IP,, inositol trisphosphate; B2AR, B,-adrenergic receptor; BARK, B-adrenergic receptor-specific kinase; PKI, PKA inhibitor peptide; Con A, concanavalin A. hydrophilic extracellular and intracellular loops. This topographical arrangement and three-component organization are characteristic of the G-protein-coupled receptor family
These receptors are in turn highly homologous to the retinal light transduction system, which consists of rhodopsin, the GTP-binding protein, transducin, and the effector, cyclic GMP-phosphodiesterase. Based on the discovery of rhodopsin kinase [lo] , a specific enzyme that phosphorylates the 'bleached' form of rhodopsin, serving to uncouple and therefore desensitize signal transduction, it was postulated that a similar kinase may exist for the adrenergic receptors. In fact, such as enzyme has been identified and purified t o homogeneity [ 111. It is a single 80000 Da polypeptide whose phosphorylating activity is insensitive to cyclic AMP, cyclic GMP, Ca? + /calmodulin and Ca? + /phospholipid. It does not phosphorylate casein and histones. Rather, it phosphorylates the agonist-occupied form of the p2-and a,-AR with a stoichiometry of 2 8 mol of phosphate/mol of receptor. From the recent cloning of B-adrenergic receptor-specific kinase (BARK) [ 121, two highly homologous but distinct clones were obtained, suggesting the presence of isoenzymes and possibly a family of receptor kinase genes. In analogy to the rhodopsin system, a series of threonines and serines in the Cterminus of the B2AR appear to serve as substrates for phosphorylation by BARK (Fig. 1 ). In addition, there are two consensus sequences for phosphorylation by PKA.
The &AR is subject to a number of other posttranslational modifications. Our current view ( Fig. 1) indicates two sites for Winked glycosylation on the extracellular N-terminus of the protein, disulphide bonds important for ligand binding, and palmitoylation of a conserved cysteine residue in the cytoplasmic C-terminus adjacent to the membrane. The functional significance of this acylation has been explored by mutagenesis experiments in which the cysteine was replaced by glycine. This non-palmitoylated mutant receptor is significantly impaired in both its ability to form the high-affinity receptor-G-protein complex and to mediate agonist-stimulated adenylyl cyclase activity 1 131.
PI.

Regirlation of hormonal responsiveness
The G-protein-coupled receptors regulate the generation of important intracellular second messengers, and as a result, the responsiveness of the system is tightly controlled. One major form of regulation is the phenomenon of 'desensitization'. Desensitization is a very general biological phenomenon where the response to a stimulus wanes over time despite the continuous presence of a stimulus of constant intensity. Three processes have been shown to be associated with the development of BAR desensitization: (i) a rapid uncoupling of the receptor from effector units which probably involves some conformational change in the receptor itself rather than phosphorylation and (iii) downregulation, which takes place over several hours and results in a net decrease in receptor number. Multiple mechanisms have been identified at this step, some of which will be discussed below. Desensitization is most frequently quantified by the loss in the ability of the receptor to stimulate its effector, adenylate cyclase. Reductions of up to 50% in maximal agoniststimulated adenylyl cyclase activity can be observed. To examine the relative contributions of the three major mechanisms operating in the rapid uncoupling step of desensitization (phosphorylation by BARK, by PKA, and receptor sequestration) Lohse, Benovic and co-workers have developed a model in which relatively specific inhibitors of these pathways were introduced into permeabilized human A431 cells [ 141. The polyanion heparin is a highly specific and effective inhibitor of BARK [15] , while the 31-amino acid PKA inhibitor peptide (PKI, 1 p~) blocks phosphorylation by PKA. Finally, in several systems concanavalin A (Con A ) has been shown to specifically inhibit receptor sequestration during agonist-induced desensitization. When these inhibitors were used alone or in combination during agonist-induced desensitization, the relative contribution of each pathway was assessed (Fig. 2) . At low agonist concentrations [ 10 nM-( -)isoprenahe] desensitization is largely due to phosphorylation by PKA. At higher concentrations of agonist [ 1 p~-( -)isoprenaline] -85-90% of the rapid desensitization response can be attributed to phosphorylation by PKA and BARK, with each kinase contributing in roughly equal proportion. Under these conditions receptor sequestration appears to play a minor role. However, when both PKA and BARK are inhibited, receptor sequestration now becomes a significant component to the desensitization response as this pathway alone is able to promote up to a 15% reduction in maximal agonist-stimulated adenylyl cyclase activity. As discussed by Lohse et al. [14] , these results indicate the redundancy in the regulatory mechanisms controlling signal transduction, and also suggest that an agonist-dependent concentration gradient regulates the degree of desensitization produced. Now we turn to the third element of desensitization, downregulation: where receptors are irreversibly lost from the cell with a corresponding decrease in receptor-stimulated adenylyl cyclase activity. Recent studies from our laboratory [16] and others [17] have begun to examine BzAR gene expression during the course of downregulation. After exposure of the hamster smooth muscle cell line DDT,MF-2 to a B-adrenergic agonist for 24 h, receptor downregulation is accompanied by a > 50% reduction in BzAR mRNA. This effect could be mimicked by the membrane-permeable analogue of cyclic AMP, dibutyryl cyclic AMP.
From this finding we wished to study in greater detail the role of the second messenger cyclic AMP in promoting BzAR down regulation in the absence of any contribution from the agonist. These studies were conducted by expressing the human BzAR cDNA in receptor-deficient hamster fibroblast cells [ 181. In such cells, exposure to dibutyryl cyclic AMP or 8-bromo-cyclic AMP for 24 h promoted a 50% reduction in PzAR number. Other agents which elevate intracellular levels of cyclic AMP such as isobutylmethylxanthine (IBMX) or forskolin, produced an identical downregulation. These data are essentially identical to the results obtained in the DDT, smooth muscle cells and indicate that cyclic AMP alone can induce receptor downregulation in the absence of agonist, and also in the absence of its own promoter.
As noted earlier, the BzAR is a substrate for phosphorylation by PKA, and contains two consensus sequences for PKA phosphorylation in the third cytoplasmic loop and the Cterminus. Synthetic peptides of these two regions can be phosphorylated in vitro by PKA, with the peptide in the third cytoplasmic loop of the receptor being the preferred substrate by about 100-fold. Since it is clear from other data that PKA plays a significant role in promoting rapid desensitization of this receptor system, we wanted to establish whether phosphorylation of these sites is also involved in the process of &AR downregulation. Therefore, these two sites in the receptor were disrupted by a site-directed mutagenesis approach. In the first mutant, which we have called PKA-I, the PKA site in the third cytoplasmic loop was disrupted by the insertion of four irrelevant amino acids between the serine (S) and arginine (R). In the second mutant, termed PKA-*, both sites of PKA phosphorylation were obliterated by substituting the serines with alanines. These mutant receptors were expressed in receptor-deficient hamster fibroblast cells and clonal lines expressing comparable levels of these mutant receptors were selected for further study.
In cells expressing either the single mutation in the third cytoplasmic loop (PKA-I ) or the double mutation (PKA-*), cyclic AMP-induced phosphorylation of the receptor was completely abolished as assessed by 32P incorporation into partially purified B2AR. These results suggested that phosphorylation by PKA occurs at these consensus sequences in vivo, in agreement with the in vitro peptide phosphorylation data. To examine the functional consequences of these mutations on down regulation, the time course of cyclic AMP-induced receptor downregulation was evaluated. In PKA-cells downregulation was noticeably delayed relative to the wild-type (Fig. 3a) . After several hours, the mutant receptors underwent downregulation at a rate which closely paralleled that of the wild-type receptors.
Essentially identical results were obtained in PKA-* cells expressing the double mutation (not shown).
From these results it is clear that phosphorylation contributes to, but is not the major factor, involved in the mechanism of receptor downregulation. Since cyclic AMP has been shown to affect mRNA levels for several genes (see references in mRNA in these stably transfected cells. After exposure to dibutyryl cyclic AMP, there was a dramatic reduction in the level of P,AR mRNA from the wild-type cells, with an identical pattern of mRNA regulation for the mutant PKA-' cells (Fig. 3b) . The same results were obtained with forskolin. This is in contrast to the observation that downregulation of the P,AR in the single mutant PKA-' is much slower than the wild-type (Fig. 3a) . Thus, the initial delay in the rate of downregulation of the mutant receptor induced by cyclic AMP is most likely due to an alteration of phosphorylation. However, the decrease in B,AR mRNA levels in response to cyclic AMP, which we also observed in DDT, cells, may be a significant factor in the mechanism of cyclic AMP-induced downregulation at these later times, as it actually preceeds the decline in receptor number. Thus, it appears that multiple mechanisms are activated following stimulation of the PzAR which contribute to the development of PzAR desensitization. Some of these pathways are completely dependent upon agonist-occupancy for their activation (e.g. sequestration, BARK phosphorylation), while others, such as the PKA pathway, can be activated through other stimuli in addition to the &AR/adenylyl cyclase system, thus affording the possibility of 'cross-talk between signalling elements in a cell. The downregulation of PzAR mRNA by the second messenger, cyclic AMP, further demonstrates the multiplicity of processes that promote P,AR desensitization. Taken together with other evidence for cyclic AMP-dependent and independent mechanisms for the regulation of PAR function not described here, these results provide an emerging picture of the complexity and variety of processes which have evolved to regulate cellular sensitivity to catecholamine action at the receptor level.
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